Drug Profile

AB 1009

Alternative Names: AB-1009

Latest Information Update: 30 Jan 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Asklepios BioPharmaceutical
Class Gene therapies
Mechanism of Action Alpha-glucosidase replacements; Gene transference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Glycogen storage disease type II
New Molecular Entity No

Highest Development Phases

Phase I/II Glycogen storage disease type II

Most Recent Events

14 Jan 2026 Genethon in-licenses AB 1009 from AskBio
08 Jan 2026 AB 1009 receives Fast Track designation for Glycogen storage disease type II [IV,Infusion] in USA
08 Jan 2026 AB 1009 receives Orphan Drug status for Glycogen storage disease type II in USA

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com